Umax

Quick links to important sections

Umax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Umax

Quick Facts

Property Description
Active ingredient Cefixime
Form Oral preparations (tablet, capsule, suspension)
Pharmacological class Third-Generation Cephalosporin Antibiotic
Common use Addressing bacterial infection
Origin Semisynthetic

The Core Identity: What is Umax Classified As?

Umax is the trade name for a medicinal product whose active compound is Cefixime, which is chemically defined as a semisynthetic beta-Lactam compound. It is classified as an Antibiotic and, more precisely, belongs to the family of Third-Generation Cephalosporins. This pharmacological classification places Cefixime among the advanced orally-active anti-infective agents, and its efficacy has been clinically recognized for its stability against common bacterial resistance mechanisms. This broad-spectrum activity is vital for an agent whose purpose is eliminating microorganisms responsible for infectious diseases.


Composition and Origin of Cefixime

The composition of Umax is defined by its single active ingredient, Cefixime (often present as Cefixime trihydrate), which is formulated for oral administration. Cefixime is a specialized semisynthetic compound, derived from an initial naturally occurring structure but chemically modified to enhance its therapeutic properties. The drug is often noted for its availability as a palatable powder for oral suspension, ensuring suitable options for difficult-to-treat pediatric patients. The medicine is also available in standard adult oral dosage forms, including the tablet and capsule.


General Therapeutic Purpose

The general purpose of Umax is to address various forms of bacterial infection by eliminating the active, replicating pathogens responsible for the illness. As a broad-spectrum agent, its primary utility is rooted in its ability to destroy the structural integrity of susceptible bacterial cells. A typical, neutral use scenario involves addressing common infections where the bacterial cause is known or suspected. This bactericidal action, common to all Third-Generation Cephalosporins, provides the essential benefit of clearing the infection at its source.

Regulatory References

  1. WHO Antibiotics Portal: Cefixime

What side effects are possible with Umax?

Possible Side Effects and Safety Information

The safety profile of Umax (Cefixime) is documented by regulatory authorities according to specific categories, outlining potential adverse reactions and safety constraints. The most frequently reported adverse effects are categorized as Common (ge 1% incidence) and primarily involve Gastrointestinal Disorders. These include diarrhea (up to 16% in some documented trials), loose stools, nausea, abdominal pain, dyspepsia, and flatulence.


System-Organ Classifications and Serious Events

Adverse reactions are officially grouped by the body system affected. Beyond the gastrointestinal effects, other systems documented to be involved include Hemic and Lymphatic (e.g., thrombocytopenia, leukopenia), Nervous (headache, dizziness, seizures), Renal (acute renal failure, transient BUN/creatinine elevations), and Immune System disorders.

Regulatory documents highlight the potential for serious adverse reactions. These clinically significant events include anaphylactic/anaphylactoid reactions (including shock), severe cutaneous reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and Clostridioides difficile-associated diarrhea (CDAD) (pseudomembranous colitis).


Population-Specific and Time-Related Safety

Official labeling defines specific safety considerations for certain patient groups. Dose modification is required for individuals with marked renal impairment. Additionally, efficacy and safety have not been established in infants under six months of age. Safety notes also state that symptoms of pseudomembranous colitis may occur during or after therapy, sometimes many weeks following the cessation of administration. Caution is advised when the drug is used by individuals with a history of colitis.

Overdose and Emergency Response

Overdose Manifestations and Risks

Regulatory documentation outlines that an overdose of Umax (Cefixime) may present with adverse reactions consistent with the drug’s known safety profile, including diarrhea and changes in stool consistency. More critically, exposure to high doses carries a documented risk of neurotoxicity, particularly manifesting as encephalopathy (brain disease). Clinical signs associated with this severe outcome include convulsions (seizures), confusion, impairment of consciousness, and movement disorders.

The risk of these serious neurological consequences is significantly increased in patients with renal impairment, as the drug is not effectively cleared from the system.


Management and Emergency Actions

Should an overdose be suspected, no specific antidote is known for Cefixime, and official labeling confirms that standard procedures like hemodialysis or peritoneal dialysis are not effective for removing the drug in significant quantities. Treatment is limited to general supportive measures and symptomatic care, which may include anticonvulsant therapy if seizures occur.

Immediate medical attention must be sought. Regulators mandate that emergency services be contacted if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Contacting the poison control helpline is also required as an immediate action.

Therapeutic Uses of Umax

What Umax Treats: Main Uses and Benefits

Umax (Cefixime) is commonly used across conditions presenting with acute episodes where additional symptomatic support is needed. Use of this medication is relevant in clinical settings that involve acute bacterial infections.

The medication is applied across domains where additional symptomatic support is needed, including conditions involving inflammatory or irritative processes in the respiratory tract, such as acute otitis media, sinusitis, and pharyngitis; urogenital tract infections, including uncomplicated UTIs; and certain systemic illnesses like typhoid fever.

“Umax supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms interfere with routine activities.”

This therapeutic role provides support that helps ease the overall symptom burden. It is applied during phases of increased distress or discomfort to help manage symptom clusters that may become intense or disruptive for both pediatric patients and adults.


Quick Fact: Support for Acute Symptomatic Phases

  • Primary Focus: Conditions characterized by periods of heightened symptoms.
  • Benefit Provided: Supports general well-being during symptomatic phases.
  • Common Use Scenario: When symptoms intensify and short-term symptomatic assistance is needed.
  • Symptom Type: Symptoms related to physical discomfort and systemic imbalance.

Regulatory References

  1. US National Library of Medicine (DailyMed)

Eligibility and Restrictions for Use

Umax (Cefixime) is an antibiotic whose use is defined by specific population eligibility rules documented in official government regulatory documents.

Eligibility Status Population/Condition Regulatory Classification
Absolute Non-Eligibility Known hypersensitivity to Cefixime, any other cephalosporin antibiotic, or a history of immediate and severe allergy to penicillin or other beta-lactam antibiotics. Contraindicated
Conditional Use Required Patients with impaired renal function (Creatinine Clearance < 60 mL/min) or a history of severe gastrointestinal disease (e.g., colitis). Restricted/Caution
Use Not Established Pediatric patients under 6 months of age. Also newborn infants (0–27 days) in some regional labels. Not Established/Not Recommended

Age-Group Eligibility is generally established for adults and pediatric patients 6 months of age or older. Older adults are eligible, but regulatory guidelines mandate that their renal function be assessed to determine if a dosage adjustment is necessary. For pregnancy (FDA Category B) and lactation, use is restricted and recommended only if clearly needed, with consideration given to temporarily discontinuing nursing during treatment.

What should I know about interactions with other medicines?

The regulatory documentation for Umax (Cefixime) outlines specific interaction patterns with other medicines and products, classifying them based on resulting pharmacokinetic outcomes and pharmacodynamic effects. These statements are derived exclusively from authoritative government regulatory sources.

Documented Pharmacokinetic Outcomes

Interacting Substance Officially Documented Outcome
Probenecid Results in a pharmacokinetic interaction that formally increases Cefixime plasma concentrations and reduces renal clearance.
Carbamazepine Co-administration is reported to lead to an official increase in Carbamazepine plasma concentrations.

Documented Pharmacodynamic Effects

  • Co-administration with anticoagulants (such as Warfarin) is associated with an official increase in prothrombin time.
  • Concomitant use with oral contraceptives is formally documented as decreasing the efficacy of the contraceptive agent.

Special Interaction Notes

  • Food: The official label notes that administration with food does not significantly alter the overall extent of Cefixime absorption (AUC).
  • Population-Specific Risk: Co-administration with other drugs known to affect renal function may increase the risk of Cefixime accumulation. This consideration is specifically noted for elderly patients and individuals with impaired renal function due to the drug’s primary elimination pathway.

No combinations are formally classified as strictly contraindicated based solely on the Cefixime interaction profile, and no mandatory administration separation windows are universally specified in regulatory labeling.

Mechanism of Action

How Umax Works: Mechanism of Action

Umax operates by inhibiting two specific enzymes: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform ( PI3 Kdelta) and Casein kinase I isoform epsilon ( CK1varepsilon). This action selectively targets the signaling within specific B-lymphocytes, as the PI3 Kdelta isoform is predominantly expressed in immune cells. By blocking these kinases, Umax interferes with critical internal signaling cascades.

The inhibition of PI3 Kdelta disrupts the B-cell receptor pathway, while CK1varepsilon inhibition destabilizes additional growth-related signals. This dual molecular interference leads to two primary cellular consequences: a reduction in proliferation and an increase in apoptosis (programmed cell death) of the targeted cells. Furthermore, Umax's mechanism modulates the cellular processes of adhesion and migration, interrupting the pathways necessary for these cells to grow and survive. This physiological modulation is restricted to the cellular and molecular domain.

Dosage and Administration Information

How to Use Umax (Cefixime)

Umax, with the active ingredient Cefixime, is administered through the oral route and is available in forms such as capsules, film-coated tablets, chewable tablets, and a powder for oral suspension. The manner in which the medicine is taken is defined by established guidelines, focusing on dosing, frequency, duration, and patient-specific adjustments.


Administration and Dosing Standards

Usage Aspect Official Instructions
Standard Adult Dose 400 mg daily, which may be taken either as a single dose once a day (QD) or divided into 200 mg doses every 12 hours (BID).
Timing Relative to Food The medication may be administered without regard to food.
Treatment Duration The typical course ranges from 7 to 14 days. For infections caused by Streptococcus pyogenes, the course must be a minimum of 10 days.

Special Procedural Requirements

Official labels detail administration rules for specific populations and forms. For pediatric patients (6 months and older), the dose is calculated based on weight at 8 mg/kg/day, which can be given as a single daily dose or two divided doses. The oral suspension requires shaking well before each use, and for treating acute otitis media, the suspension is the mandated form, not the tablet or capsule. If a dose is missed, instructions state to skip it and resume the regular schedule, with strict instruction not to take a double dose to compensate.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Umax (Cefixime)

This section summarizes the structure and type of clinical evidence available for Umax, focusing on trials cited by official sources, without providing clinical advice or treatment recommendations. Research describing the medicine was studied for various acute infections, exploring specific patient groups and measuring how symptoms evolved over defined periods.


Research Exploring Use in Common Acute Infections

The research base for conditions like Acute Otitis Media (AOM) relies heavily on Randomized Controlled Trials (RCTs) and comparative studies, primarily enrolling children aged 6 months and older. These trials examined outcomes related to clinical cure or improvement rates and the microbiological eradication rates for bacteria. Studies comparing Cefixime against other antibacterial agents described patterns of difference in clinical measurements when dealing with specific bacterial species. For Pharyngitis and Tonsillitis, research explored microbiological response within the studied populations following a defined course of use.

Evidence Supporting Use in Urogenital and Systemic Infections

Research on Uncomplicated Urinary Tract Infections (UTIs) has often involved prospective trials that were evaluated in adult and young women populations. The studies examined primary endpoints related to microbiological success and clinical success. For Typhoid Fever (Enteric Fever), evidence is largely derived from comparative clinical trials, exploring outcomes such as time to fever clearance and rates of clinical failure or relapse. Findings in this area described variation when Cefixime was studied for comparison against certain other drug classes, and the certainty remains low for some comparisons due to the nature and scale of the trials available.


Long-Term Research and Durability of Study Findings

The majority of clinical trials for Umax were evaluated in research settings exploring short-term symptom changes and acute episodes. The follow-up durations for these core studies were limited, and consequently, long-term effects are not fully established by the available research base. There is limited information regarding the durability of outcomes beyond the immediate post-treatment period for most indications.

Key Evidence Gaps and Areas of Uncertainty

Evidence quality varies across studies, particularly for conditions like typhoid fever, where the certainty of findings is often noted as low for some comparisons. Furthermore, because many definitive trials are older, the findings were mixed when extrapolated to areas currently experiencing high rates of antimicrobial resistance, which may affect the generalizability of some research.

Key Studies & References

  1. Is cefixime (Cefixime) effective for treating urinary tract infections (UTIs)? - Dr.Oracle
  2. Cefixime for the prophylaxis of urinary tract infections in children with malformative uropathies: an open study
  3. Clinical Effectiveness and Safety of Cefixime in Managing Typhoid Fever in Indian Population: A Real-world Evidence Study

Frequently Asked Questions (FAQ)

Common questions about Umax (FAQ)


Q: Is it necessary to avoid alcohol completely while using Umax?

A: Official prescribing information for Umax (Cefixime) generally focuses on documented drug-to-drug interactions. These documents do not typically contain an explicit prohibition against consuming alcohol while taking the medicine. Individual considerations regarding alcohol consumption are best discussed with a healthcare professional.


Q: Does Umax affect birth control pills or other hormonal medications?

A: Yes, official documents have noted a potential interaction. Cefixime may decrease the efficacy of hormonal contraceptives, such as birth control pills, patches, rings, or injections. Patients using hormonal birth control should be aware of this potential interaction.


Q: What pain relievers or over-the-counter medicines interact with Umax?

A: Regulatory documents do not generally highlight interactions between Cefixime and common over-the-counter pain relievers like ibuprofen. However, Umax has been shown to affect the efficacy of anticoagulants (blood thinners), which are a type of medicine sometimes taken for pain or other conditions.


Q: Is Umax considered safe during pregnancy according to regulatory bodies?

A: The FDA classifies Cefixime as Pregnancy Category B. The official classification suggests that use is recommended only if clearly needed and the potential benefit justifies the potential risk.


Q: Can Umax be used while breastfeeding?

A: It is not definitively known if Cefixime is excreted into human milk. Official documents advise that consideration should be given to temporarily discontinuing nursing during the period of treatment. The official recommendation is based on the uncertainty of potential excretion into human milk.


Q: What if I have an allergic reaction to Umax—what are the signs?

A: Signs of a possible allergic reaction documented in regulatory materials include rash, hives, itching, difficulty breathing or swallowing, wheezing, and swelling of the face, lips, tongue, or throat. These are considered serious and require prompt medical attention.


Q: Is it important to take Umax at the exact same time every day?

A: The prescribed schedule for Umax is typically once daily (QD) or twice daily (BID). While the exact time does not need to be tracked, taking the medicine at a consistent time each day is generally considered helpful for maintaining the required level of the medicine in the body.


Q: Does Umax contain any common allergens, such as lactose or gluten?

A: The official documentation confirms that chewable tablet forms of Cefixime are known to contain aspartame, which is a source of phenylalanine (relevant for patients with PKU). Information on other excipients, such as lactose or gluten, can vary by dosage form and manufacturer, and is listed in the full package insert.


Q: Can Umax be taken with vitamins or dietary supplements?

A: Regulatory documents do not typically contain general warnings about the use of Cefixime with standard vitamins or most common dietary supplements. Formal interaction studies for every single supplement are not readily available. Information regarding all supplements is typically reviewed by a healthcare provider.


Q: What are the official guidelines regarding Umax and driving or operating machinery?

A: Official guidelines advise against operating machines or driving a vehicle if certain side effects occur. These include effects related to the central nervous system, such as confusion, movement disorders, or convulsions. A patient’s ability to drive or operate machinery may be affected by these reported side effects.


Q: Can Umax be taken by adults of all ages?

A: The medicine is officially indicated for use in adults and children over six months of age. For older adults, official guidelines advise that renal function be assessed to determine if a dosage adjustment is necessary.


Q: Is Umax intended for short-term use only?

A: Yes, Umax is intended for short-term use. Regulatory instructions define a fixed duration of use, typically ranging from 7 to 14 days, based on the specific type of bacterial infection being addressed.


Q: How quickly does Umax start to work after the first use?

A: The medicine's active compound, Cefixime, is documented to reach its peak concentration in the bloodstream approximately 2 to 6 hours after being taken. This is when the medicine has reached its highest measurable level in the body.


Q: Why do some people compare Umax to [Similar Drug Name]?

A: Official classification documents describe Cefixime as a Third-Generation Cephalosporin antibiotic. This places it in a class of drugs that share a similar mode of action and spectrum of activity to other agents in this group, such as Cefotaxime, leading to common comparisons.


Q: Is it common to experience sleep changes while taking Umax?

A: Official adverse reaction reports list side effects primarily involving the gastrointestinal system (like diarrhea) and the nervous system (like headache and dizziness). Sleep changes, such as insomnia or drowsiness, are not typically reported among the frequently observed reactions. The most commonly reported adverse effects are associated with the gastrointestinal system.


Q: How often are serious adverse effects reported for Umax in official documents?

A: The frequency of adverse events reported in clinical trials for Cefixime has varied, with general incidence rates for all side effects ranging from approximately 2.7% to 48.2% across different studies. Serious adverse reactions like anaphylaxis or severe skin conditions (SJS/TEN) are listed in official warnings but are generally reported as rare.


Q: Does Umax affect blood pressure levels?

A: Changes in blood pressure are not listed among the commonly documented adverse effects of Cefixime in the official prescribing information. The most commonly reported adverse effects are associated with the gastrointestinal system.


Q: Is weight gain or loss a documented expectation with Umax use?

A: Weight changes (gain or loss) are not listed among the commonly documented adverse effects of Cefixime in the official prescribing information. Reported adverse reactions primarily involve the gastrointestinal and central nervous systems.


Q: Does Umax cause dry mouth or changes in taste?

A: Dry mouth or changes in taste are not commonly listed in the official prescribing information among the most frequently reported adverse effects of Cefixime. The most commonly reported adverse effects are related to the digestive system, such as diarrhea and loose stools.


Q: Are there any known differences in how Umax affects men versus women?

A: Official prescribing information and pharmacokinetic studies for Cefixime do not typically highlight significant, generalized differences in how the medicine affects adult men versus women. The standard adult dosing remains the same for both sexes.


Q: What does it mean that Umax is a 'scheduled' drug?

A: Umax is generally classified as a prescription-only medication in most regions, meaning it can only be legally dispensed with a valid prescription from an authorized health professional. It is not classified as a controlled substance (often referred to as a 'scheduled drug').


Q: Do regulatory bodies require special monitoring while taking Umax?

A: Yes, regulatory documents do require special monitoring in certain situations. This includes checking prothrombin time for patients taking anticoagulants and closely monitoring patients with pre-existing renal (kidney) or hepatic (liver) impairment.


Q: Is Umax associated with any changes in mood or behavior?

A: Serious nervous system side effects have been reported, including the risk of encephalopathy (which can involve confusion, convulsions, and movement disorders), particularly in patients with pre-existing kidney impairment. General changes in mood or typical behavior are not commonly listed in the official documents.


Q: Where can I find summaries of the research evidence for Umax?

A: Summaries of the key efficacy and safety research supporting Cefixime's approval are contained within the Regulatory Review Documents filed by the manufacturer with government agencies. Examples include the FDA New Drug Application (NDA) summaries or the EMA Scientific Discussions.


Q: Does Umax interact with natural or herbal remedies?

A: Official drug labels generally focus on established drug-to-drug interactions based on formal studies. They do not typically contain specific interaction warnings regarding Cefixime and a wide range of natural or herbal remedies. Information regarding all supplements is typically reviewed by a healthcare provider.

How should Umax be stored and disposed of?

How to Store and Dispose of Umax?

The storage and disposal requirements for Umax (cefixime) are defined by specific regulatory guidelines to ensure product quality.

Official Storage Conditions

Dosage Form Required Storage Environment
Tablets/Capsules/Powder Controlled Room Temperature (20 C to 25 C). Excursions up to 30 C are permitted.
Reconstituted Suspension May be stored at room temperature or refrigerated (up to 25 C).

The product must always be stored in a closed container and it is a mandatory requirement to keep Umax out of the sight and reach of children. All formulations must be protected from freezing, as this is a prohibited storage environment.

Stability and Disposal

The reconstituted oral suspension is stable for a maximum of 14 days, after which any unused portion must be discarded. For disposal of unused or expired medication, standard regulatory guidance advises mixing the product with an undesirable substance before discarding it in the household trash. Patients should consult a pharmacist for information on local medication take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Umax found in:

A-Z Index: